Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 12/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436532 | 0.87 | STING1 (0.68) | STING1 | |
| SCHEMBL22135066 | 0.87 | STING1 (0.57) | STING1USP2EPHX2 | |
| SCHEMBL28522082 | 0.86 | STING1 (0.56) | STING1USP2KDM4E | |
| Bromide SCHEMBL23327843 | 0.86 | STING1 (0.67) | STING1 | |
| Bromide SCHEMBL29619902 | 0.86 | STING1 (0.67) | STING1 | |
| SCHEMBL22150070 | 0.83 | STING1 (0.75) | STING1 | |
| SCHEMBL22135067 | 0.81 | STING1 (0.57) | STING1KDM4EALDH1A1CYP2D6 | |
| SCHEMBL22312656 | 0.81 | STING1 (0.62) | STING1 | |
| SCHEMBL22150413 | 0.80 | STING1 (0.49) | STING1USP2KDM4ETDP1 | |
| Bromide SCHEMBL28599228 | 0.80 | STING1 (0.49) | STING1USP2KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189820-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189820-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885USP2 701/4885KDM4E 2480/4885 |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | STING1 3127/4885USP2 701/4885KDM4E 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.